Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2014  |  Volume : 10  |  Issue : 1  |  Page : 112-120

Preclinical evaluation of [ 111 In]-DOTA-trastuzumab for clinical trials

Radiopharmacy Research Group, Radiation Application Research School, Nuclear Science and Technology Research Institute, 11365-3486, Tehran, Iran

Correspondence Address:
Amir Reza Jalilian
Nuclear Science Research School, Nuclear Science and Technology Research Institute, 11365-3486, Tehran
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0973-1482.131434

Rights and Permissions

Context: Herceptin and its fragments have been radiolabeled and used in the imaging of human epidermal growth factor receptor 2 (HER2)/neu-positive tumors and development of diagnostic kits is of great importance in radiopharmacy. Aims: In this study, 111 In-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-trastuzumab ( 111 In-DOTA-trastuzumab) was successively prepared and evaluated for ultimate use in the HER2 antigen imaging in oncology. Settings and Design: The conjugate was prepared, labeled and evaluated using in vitro (radioimmunoassay [RIA], enzyme-linked immunosorbent assay (ELISA), stability, binding, internalization)/in vivo (bio-distribution, single-photon emission computed tomography [SPECT]) experiments. Materials and Methods: 111 In-DOTA-trastuzumab was prepared followed by determination of radiochemical purity (RCP), integrity of protein, immunoreactivity of radiolabeled antibody with HER2/neu antigen (by SkBr3 cell line binding and RIA methods) were determined followed by stability tests, internalization studies and the tissue bio-distribution determination in wild-type rats as well as SPECT imaging in SkBr3-bearing mice. Statistical Analysis Used: All values were expressed as mean ± standard deviation (mean ± SD) and the data were compared using Student's t-test. Statistical significance was defined as P < 0.05. Results: 111 In-DOTA-trastuzumab was prepared (RCP >95 ± 0.5%, S.A. 5.3 μCi/μg) with the average number of chelators per antibody of 6:1 showing significant immune-reactivity retention using ELISA. In vitro stability was >90% in phosphate buffered saline and 80 ± 0.5% in serum over 48 h. Cell binding was significant (>0.79). In vitro internalization reached up to %12-13 in 10 h. Significant tumor uptake was observed. Conclusions: In vitro and in vivo/SPECT imaging in SkBr3-bearing mice demonstrated that 111 In-DOTA-trastuzumab is a potential compound for molecular imaging of SPECT for diagnosis and follow-up of HER2 expression in oncology.

Abstract in Chinese

铟111标记的曲妥珠单抗临床试验的前期临床试验评估 背景:赫赛汀及其片段被同位素标记后用于人表皮生长因子受体2(HER2)/neu阳性肿瘤的成像,以及诊断配件的发展在放射性药物学中都有重要地位。 目的:本研究中,铟111-1,4,7,10-轮环藤宁 -1,4,7,10-四乙酸酸曲妥珠单抗依次准备和评估最终用于肿瘤学中HER2抗原成像。 方法设计:事先准备好结合配对,做好标签,离体评估(ELISA法)/(SPECT法)。 材料和方法:准备好铟111标记的曲妥珠单抗,测定放射化学纯度(RCP),蛋白完整性,放射性同位素标记抗体HER2/neu抗原的免疫反应性(SkBr3细胞株整合和RIA法),随后进行稳定性试验,内化研究和组织生物分布测定,对像包括野生大鼠和SPECT成像的SkBr3小鼠。 统计方法:所有值表示为平均值±标准差,用t-检验。显著性差异定义P<0.05。 结果:铟111标记的曲妥珠单抗(RCP >95 ± 0.5%, S.A. 5.3 μCi/μg),每抗体平均螯合剂6:1有明显的免疫反应性(ELISA法)。48小时离体稳定性:在磷酸盐缓冲盐水中>90%,血清中80% ± 0.5%。细胞整合明显:(>0.79)。10小时离体内化率12%~13%。可观察到明显的肿瘤摄取。 结论:在SkBr3小鼠离体和体内的/SPECT成像表明,铟111标记的曲妥珠单抗在肿瘤学HER2表达的诊断和随访、SPECT分子成像方面是一种有潜在功能的化合物。 关键词:生物学分布,铟111,生成,SkBr3细胞,单光子发射计算体层摄影,曲妥珠单抗

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded146    
    Comments [Add]    

Recommend this journal